REUTERS/Mike Segar - Technician Mike Lattari prepares a flow cell slide for loading onto a genetic sequencing machine at a Regeneron Pharmaceuticals Inc. laboratory at the biotechnology company's headquarters in Tarrytown, New York March 24, 2015. Drug manufacturers have begun amassing enormous troves of human DNA in hopes of significantly shortening the time it takes to identify new drug candidates, a move some say is transforming the development of medicines. The efforts will help researchers identify rare genetic mutations by scanning large databases of volunteers who agree to have their DNA sequenced and to provide access to detailed medical records. Picture taken March 24, 2015.

Blog Post

The consequences of cutting corporate R&D budgets

September 30, 2015, William A. Galston

Recent research suggests that large corporations have reduced their investment in basic research. In this post, William Galston looks at the implications of this shift. 

View All Research on Corporations ›Show 10 More